1 任成山, 王关嵩, 钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
2 Halpin DMG, Criner GJ, Papi A, et al. The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease [J]. Am J Respir Crit Care Med, 2021, 203(1): 24-36.
3 Linden D, Guo-Parke H, Coyle PV, et al. Respiratory viral infection:a potential “missing link” in the pathogenesis of COPD[J]. Eur Respir Rev, 2019, 28(151): 180063.
4 Falsey AR, Walsh EE, Esser MT, et al. Respiratory syncytial virus-associated illness in adults with advanced chronic obstructive pulmonary disease and/or congestive heart failure[J]. J Med Virol, 2019, 91(1): 65-71.
5 周寅川, 荣 蓉, 黄祎丹, 等. 慢性阻塞性肺疾病急性加重期患者出院后30d内再入院的影响因素分析及Nomogram模型构建[J]. 实用心脑肺血管病杂志, 2020, 28(8): 57-63.
6 Gong C, Yang Y, Chen M, et al. Effect of procalcitonin on the prognosis of patients with COPD[J]. Biomed Rep, 2020, 12(6): 313-318.
7 慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组. 慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2017年更新版)[J]. 国际呼吸杂志, 2017, 37(14): 1041-1057.
8 Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations[J]. Clin Chest Med, 2020, 41(3): 421-438.
9 Paes B, Carbonell-Estrany X. Respiratory syncytial virus prophylaxis for children with chronic lung disease: have we got the criteria right?[J]. Expert Rev Anti Infect Ther, 2019, 17(4): 211-222.
10 Prasad N, Walker TA, Waite B, et al. Respiratory syncytial virus-associated hospitalizations among adults with chronic medical conditions [J]. Clin Infect Dis, 2021, 73(1): e158-e163.
11 郝燕燕, 邹晓静, 李献超. 慢性阻塞性肺疾病患者呼吸道合胞病毒感染后血清TH2类细胞因子及肺表面活性蛋白D水平的研究[J]. 中国卫生检验杂志, 2019, 29(6): 716-719.
12 林 静, 陈志敏. 儿童腺病毒性肺炎与呼吸道合胞病毒肺炎的研究进展[J]. 实用临床医学, 2020, 21(3): 95-98.
13 Baraldi E, Bonadies L, Manzoni P. Evidence on the link between respiratory syncytial virus infection in early life and chronic obstructive lung diseases[J]. Am J Perinatol, 2020, 37(S02): S26-S30.
14 袁胜蓝, 梁民勇, 秧茂盛. 慢性阻塞性肺疾病急性加重期患者炎性标志物的研究进展[J]. 中国当代医药, 2019, 26(34): 31-34.
15 丁 巍, 王文艺, 邬 超, 等. 慢性阻塞性肺疾病肺感染患者血清细胞因子及肺功能指标变化情况[J]. 华南预防医学, 2020, 46(5): 586-588, 592.
16 Nuriev R, Johansson C. Chemokine regulation of inflammation during respiratory syncytial virus infection[J]. F1000Res, 2019, 32(8):1831-1837.
17 刘宇阳摘, 陈勇校. 基于聚合物结构的佐剂配伍呼吸道合胞病毒融合蛋白可诱导巨噬细胞产生多种信号传导途径[J]. 微生物学免疫学进展, 2019, 47(2): 1.
18 彭 程, 黎金雨, 赵 云, 等. 呼吸道合胞病毒毛细支气管炎患儿中TREM-1/DAP12通路关键信号节点的表达[J]. 中国感染控制杂志, 2020, 19(5): 433-439.
19 Marcandalli J, Fiala B, Ols S, et al. Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus[J]. Cell, 2019, 176(6): 1420-1431.
20 Satia I, Cusack R, Greene JM, et al. Prevalence and contribution of respiratory viruses in the community to rates of emergency department visits and hospitalizations with respiratory tract infections, chronic obstructive pulmonary disease and asthma[J]. PLoS One, 2020, 15(2): e0228544.